Crystallisation development provides the first-choice opportunity to innovative particle design

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Johnson Matthey
2003 Nolte Drive
West Deptford
NJ 08066-1742

44 (0) 1223 226160

London Address: 10 Eastbourne Terrace, London, W2 6LG

Email: [email protected]

Web address: matthey.com

Johnson Matthey is a leader in sustainable technologies. We apply our cutting-edge science to create solutions with our customers that make a real difference to the world around us. We work globally with our pharmaceutical customers to deliver complex chemistry solutions for a healthier world. We produce sophisticated APIs for life-changing drugs; our expertise in controlled substances helps combat chronic pain and we employ decades of catalysis know-how to enable faster, cleaner, more efficient reactions. Our custom pharma solutions offering and worldwide manufacturing capabilities help get your drugs to market faster, making a real difference to the quality of life.

Crystallisation development provides the first-choice opportunity to innovative particle design

Please log in for more information